Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Cell-based influenza vaccines: an effective vaccine option for under 60-year-olds].
Gärtner BC, Beier D, Gosch G, Wahle K, Wendt L, Förster LC, Schmidt KJ, Schwarz TF. Gärtner BC, et al. Among authors: schwarz tf. Wien Klin Wochenschr. 2024 Feb;136(Suppl 2):35-42. doi: 10.1007/s00508-024-02327-3. Epub 2024 Feb 23. Wien Klin Wochenschr. 2024. PMID: 38393348 Free PMC article. German.
Reply to letter to editor by Yin et al.
Gärtner BC, Kwetkat A, Beier D, Wahle K, Schmidt KJ, Schwarz TF. Gärtner BC, et al. Among authors: schwarz tf. Vaccine. 2024 Apr 2;42(9):2115-2116. doi: 10.1016/j.vaccine.2024.01.051. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38360472 No abstract available.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrøm V. Curran D, et al. Among authors: schwarz tf. Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb. Influenza Other Respir Viruses. 2024. PMID: 38314063 Free PMC article. Clinical Trial.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Among authors: schwarz tf. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. Among authors: schwarz tf. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
160 results